87 related articles for article (PubMed ID: 26178438)
1. Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs.
Fulkerson CM; Dhawan D; Jones DR; Marquez VE; Jones PA; Wang Z; Wu Q; Klaunig JE; Fourez LM; Bonney PL; Knapp DW
Vet Comp Oncol; 2017 Mar; 15(1):226-236. PubMed ID: 26178438
[TBL] [Abstract][Full Text] [Related]
2. Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors.
Klecker RW; Cysyk RL; Collins JM
Bioorg Med Chem; 2006 Jan; 14(1):62-6. PubMed ID: 16143537
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine.
Holleran JL; Parise RA; Joseph E; Eiseman JL; Covey JM; Glaze ER; Lyubimov AV; Chen YF; D'Argenio DZ; Egorin MJ
Clin Cancer Res; 2005 May; 11(10):3862-8. PubMed ID: 15897587
[TBL] [Abstract][Full Text] [Related]
4. 6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells.
Flesner BK; Kumar SR; Bryan JN
BMC Vet Res; 2014 Dec; 10():290. PubMed ID: 25480665
[TBL] [Abstract][Full Text] [Related]
5. Low dose Zebularine treatment enhances immunogenicity of tumor cells.
Liu H; Xue ZT; Sjögren HO; Salford LG; Widegren B
Cancer Lett; 2007 Nov; 257(1):107-15. PubMed ID: 17768004
[TBL] [Abstract][Full Text] [Related]
6. A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice.
Beumer JH; Joseph E; Egorin MJ; Parker RS; D'argenio DZ; Covey JM; Eiseman JL
Clin Cancer Res; 2006 Oct; 12(19):5826-33. PubMed ID: 17020990
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
8. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma.
Herranz M; Martín-Caballero J; Fraga MF; Ruiz-Cabello J; Flores JM; Desco M; Marquez V; Esteller M
Blood; 2006 Feb; 107(3):1174-7. PubMed ID: 16239434
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs.
Jay AR; Krotscheck U; Parsley E; Benson L; Kravitz A; Mulligan A; Silva J; Mohammed H; Schwark WS
Am J Vet Res; 2013 Nov; 74(11):1450-6. PubMed ID: 24168312
[TBL] [Abstract][Full Text] [Related]
10. Toxicity associated with epirubicin treatments in a large case series of dogs.
Marrington AM; Killick DR; Grant IA; Blackwood L
Vet Comp Oncol; 2012 Jun; 10(2):113-23. PubMed ID: 22236353
[TBL] [Abstract][Full Text] [Related]
11. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.
Yoo CB; Chuang JC; Byun HM; Egger G; Yang AS; Dubeau L; Long T; Laird PW; Marquez VE; Jones PA
Cancer Prev Res (Phila); 2008 Sep; 1(4):233-40. PubMed ID: 19138966
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tolerability of aminosidine after repeated administrations using an optimal dose regimen in healthy dogs and in dogs with leishmaniosis.
Athanasiou LV; Batzias GC; Saridomichelakis MN; Delis G; Soubasis N; Kontos VI; Rallis TS
Vet Parasitol; 2014 Sep; 205(1-2):365-70. PubMed ID: 24998095
[TBL] [Abstract][Full Text] [Related]
13. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
15. Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs.
Flory AB; Rassnick KM; Balkman CE; Kiselow MA; Autio K; Beaulieu BB; Lewis LD
Am J Vet Res; 2008 Oct; 69(10):1316-22. PubMed ID: 18828689
[TBL] [Abstract][Full Text] [Related]
16. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Ogilvie GK; Moore AS; Chen C; Ciekot PA; Atwater SW; Bergman PJ; Walters LM
J Am Vet Med Assoc; 1994 Aug; 205(4):570-3. PubMed ID: 7961092
[TBL] [Abstract][Full Text] [Related]
17. DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine.
Meador JA; Su Y; Ravanat JL; Balajee AS
Carcinogenesis; 2010 Feb; 31(2):184-91. PubMed ID: 19933707
[TBL] [Abstract][Full Text] [Related]
18. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.
Marquez VE; Kelley JA; Agbaria R; Ben-Kasus T; Cheng JC; Yoo CB; Jones PA
Ann N Y Acad Sci; 2005 Nov; 1058():246-54. PubMed ID: 16394141
[TBL] [Abstract][Full Text] [Related]
19. Comparative plasma dispositions of ivermectin and doramectin following subcutaneous and oral administration in dogs.
Gokbulut C; Karademir U; Boyacioglu M; McKellar QA
Vet Parasitol; 2006 Feb; 135(3-4):347-54. PubMed ID: 16280198
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
